Femasys Inc. (NASDAQ:FEMY) Stock Short Interest Falls 70.0%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 49,266 shares, a decrease of 70.0% from the October 15th total of 164,106 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 100,794 shares, the short-interest ratio is presently 0.5 days.

Femasys Stock Up 1.4%

FEMY stock traded up $0.02 during midday trading on Friday, hitting $1.42. The stock had a trading volume of 52,887 shares, compared to its average volume of 251,829. The business has a 50-day moving average of $1.99 and a two-hundred day moving average of $5.67. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.14 and a quick ratio of 0.55. The firm has a market cap of $11.90 million, a price-to-earnings ratio of -0.40 and a beta of -2.13. Femasys has a 52-week low of $1.25 and a 52-week high of $20.80.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.07. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.62 million.

Analyst Ratings Changes

A number of research firms have recently weighed in on FEMY. Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Lake Street Capital lowered their price target on Femasys to $10.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th. Wall Street Zen lowered Femasys from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Finally, Maxim Group dropped their price objective on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.00.

About Femasys

Femasys Inc. is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures. Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.